Fifty-three years of research. Now in a bottle.
Professor Vladimir Khavinson spent a career documenting how short-chain peptides restore the gene expression that age, stress, and cumulative damage deplete. He published 775 papers and filed 196 patents. No consumer product was built on that research — until now.
Opticeuticals is the consumer category that brings Khavinson-lineage bioregulator compounds to market for the first time — cGMP manufactured, per-batch verified, and available over the counter.
Professor Vladimir Khavinson. 1946–2024.
Director of the St. Petersburg Institute of Bioregulation and Gerontology. Member of the Russian Academy of Sciences. Author of 775 peer-reviewed publications spanning 53 years of uninterrupted research into short-chain peptide bioregulators.
His central finding: short-chain peptides — two to seven amino acids — cross cell membranes, enter the nucleus, and bind directly to DNA promoter sequences. They activate tissue-specific gene expression that aging, disease, and cumulative stress have suppressed. They do not alter the underlying DNA. They restore what was already there.
This is endogenic pharmacology. The science of healing from within.
Fifty-three years of uninterrupted research.
Khavinson begins peptide bioregulator research at the Soviet Military Medical Academy, St. Petersburg.
First published findings on tissue-specific peptide gene expression modulation in peer-reviewed journals.
St. Petersburg Institute of Bioregulation and Gerontology established. Khavinson appointed Director.
Epithalon synthesized and documented — the first peptide shown to activate telomerase in human somatic cells.
775th published paper. 196 patents filed across Russia, US, Europe, Canada, and Japan.
GHK-Cu research lineage reaches 50 years of continuous peer-reviewed publication.
Professor Vladimir Khavinson passes. The research lineage continues through the institutions and companies he influenced.
Opticeuticals — the first consumer category built on Khavinson-lineage compounds — launches in the US market.
Four compound classes. Decades of published research behind each.
Every Opticeutical is built around a compound from the Khavinson research lineage. The compound targets a specific biological mechanism. The mechanism addresses a specific tissue. The research is published, indexed, and publicly accessible.
53 years of published research. Documents activation of collagen synthesis, dermal fibroblast signaling, and angiogenesis. The most extensively studied bioregulator in the Khavinson lineage.
A2A adenosine receptor activation. Published across wound repair, barrier restoration, and anti-inflammatory cascades. Named among the top-trending skincare compounds globally in 2025.
The pineal peptide. First compound documented to activate telomerase in human somatic cells. Published research spans longevity, circadian regulation, and cellular aging.
Gastrointestinal peptide with documented systemic tissue repair activity. Extensive published research across musculoskeletal, tendon, and barrier tissue outcomes.
Opticeuticals extends the Khavinson lineage. It does not claim it.
Atumnus LLC identified the compounds. We formulated protocols around them under cGMP discipline. We registered US observational studies to generate clinical data on them. We built the category infrastructure — the standard, the delivery systems, the institutional science archive — to support them.
Khavinson's research belongs to the scientific record. What Opticeuticals built is the consumer pathway to it.
Our position
"We are not making claims. We are in the process of proving them."
Opticeuticals operates within the DSHEA framework. Observational studies registered on ClinicalTrials.gov. Patent portfolio pending. Science archive at endogenicpharmacology.com.
The research lineage is the foundation. Opticeuticals is what comes next.
Six decades of published science. Consumer-accessible for the first time. cGMP manufactured. Per-batch verified. US observational studies registered.